Quality measures in heart failure

Core Measures - The HF Report Card

• LV Function Assessment:
  • Echocardiogram or equivalent must be documented to confirm diagnosis and guide therapy.
  • Differentiates HFrEF (LVEF ≤ 40%) from HFpEF (LVEF ≥ 50%).
• Guideline-Directed Medical Therapy (GDMT) for HFrEF (LVEF ≤ 40%):
  • ACE Inhibitor or ARB: Prescribed at discharge unless contraindicated.
  • Beta-Blocker: Evidence-based options (Carvedilol, Metoprolol Succinate, Bisoprolol) prescribed for stable patients.
  • Aldosterone Antagonist: For patients with LVEF ≤ 35% on standard therapy.
• Patient Education:
  • Counseling on medication adherence, dietary sodium restriction (< 2g/day), and daily weight monitoring.
• Follow-up:
  • Scheduled post-discharge appointment, typically within 7-14 days.

⭐ For USMLE purposes, remember that prescribing both an ACE inhibitor (or ARB) and a beta-blocker for a patient with HFrEF (LVEF ≤ 40%) is a critical quality indicator. Not doing so without a documented, valid contraindication is a common test question scenario highlighting a gap in care.

Discharge & Transitions - The Hand-off

Effective hand-offs are crucial to reduce readmissions. Key components include education, medication review, and scheduled follow-up.

• Core Discharge Education (Teach-back method):

  • Diet: Sodium <2 g/day, Fluids <2 L/day.
  • Monitoring: Daily weights. Report gain >3 lbs/day or >5 lbs/week.
  • Symptoms: Recognize worsening dyspnea, edema, fatigue.

• Medication Adherence:

  • Provide a simplified, written list of all medications (GDMT).
  • Verify patient understanding of doses and purpose.

• Follow-up Coordination:

  • Appointment scheduled with PCP/Cardiology within 7-14 days.
  • Clear instructions on who/when to call for problems.

⭐ High-Yield: Transitional care services and a scheduled follow-up within 7 days of discharge can significantly reduce 30-day readmission rates for HF patients.

📌 Mnemonic: D.E.A.L.

• Diet & daily weights
• Exercise as able
• Appointment for follow-up
• Log symptoms & know when to call

Medication Safety - Avoiding Harm

• NSAIDs (e.g., Ibuprofen, Naproxen)

  • Cause Na⁺ and water retention, ↑ systemic vascular resistance.
  • Blunt efficacy of diuretics and ACE inhibitors/ARBs.
  • ⚠️ High risk of precipitating acute decompensation.

• Thiazolidinediones (TZDs) (e.g., Pioglitazone, Rosiglitazone)

  • Cause significant fluid retention, worsening edema and congestion.
  • Black box warning for use in NYHA Class III/IV HF.

• Non-Dihydropyridine Calcium Channel Blockers

  • Verapamil & Diltiazem: Potent negative inotropic effects.
  • Avoid in HFrEF (LVEF < 40%). May be used cautiously in HFpEF for rate control.

• Certain Antiarrhythmics

  • Most Class I (e.g., Flecainide) and Class III (e.g., Sotalol, Dronedarone) agents have negative inotropic or proarrhythmic risks.
  • Amiodarone and Dofetilide are generally considered the safest antiarrhythmics in HFrEF.

⭐ High-Yield: The use of non-dihydropyridine calcium channel blockers like diltiazem or verapamil is contraindicated in patients with HFrEF due to their negative inotropic effects, which can worsen cardiac output and precipitate failure.

High‑Yield Points - ⚡ Biggest Takeaways

• ACE inhibitor or ARB is prescribed for all patients with left ventricular systolic dysfunction (LVSD).
• An LVEF assessment must be documented for all heart failure patients.
• Beta-blockers are prescribed for stable patients with LVSD unless contraindicated.
• Aldosterone antagonists are indicated in patients with LVEF ≤35% or post-MI heart failure.
• Comprehensive discharge instructions including diet, medication, and follow-up are critical.
• Smoking cessation counseling should be provided and documented for all current smokers.